Autres langues MBX Biosciences, Inc.

Actions

MBX

US55287L1017

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 21:46:29 16/07/2026			Varia. 5j.	Varia. 1 janv.
58,56 ^USD	-3,49%		-11,44%	+84,50%

13/07	MBX Biosciences nomme Steve Hoerter au poste de PDG ; Kent Hawryluk quitte ses fonctions	MT
13/07	MBX Biosciences, Inc. annonce un changement de direction générale, effectif au 13 juillet 2026	CI

Autres langues

13/07	MBX Biosciences Appoints Steve Hoerter as CEO; Kent Hawryluk Steps Down
13/07	MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
13/07	MBX Biosciences, Inc. Announces CEO Changes, Effective July 13, 2026
13/07	MBX Biosciences, Inc. Announces Management Changes, Effective July 13, 2026
13/07	MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Microcap Value Benchmark Index
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell 2000 Value Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell Microcap Growth Benchmark Index
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell 2000 Growth Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell 3000E Growth Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell 3000E Value Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell 3000 Value Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell 3000 Growth Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Small Cap Comp Value Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell 2500 Value Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell Small Cap Comp Growth Benchmark
29/06	MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell 2500 Growth Benchmark
12/06	MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell
12/06	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
12/06	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential PTH Replacement Therapy In Chronic Hypoparathyroidism
01/06	MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
26/05	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
11/05	Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing
11/05	MBX Biosciences : May 2026 Obesity Day Presentation – Final
11/05	MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing